US · BDX
Becton, Dickinson and Company
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Franklin Lakes, NJ 07417-1880
- Website
- bd.com
Price · as of 2025-09-30
$149.31
Market cap 63.94B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $194.29 | +30.13% |
| Intrinsic Value(DCF) | $60.66 | -59.37% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $93.52 | -37.36% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $44.12 | $90.26 | $11.74 | $21.59 | $81.90 |
| 2012 | $48.12 | $89.60 | $10.59 | $16.53 | $55.01 |
| 2013 | $68.66 | $97.94 | $11.10 | $23.61 | $81.75 |
| 2014 | $89.88 | $111.13 | $13.98 | $18.48 | $77.99 |
| 2015 | $99.65 | $104.24 | $13.93 | $0.00 | $99.45 |
| 2016 | $111.20 | $114.24 | $251.22 | $0.00 | $131.23 |
| 2017 | $149.06 | $147.54 | $70.99 | $3.33 | $25.47 |
| 2018 | $161.16 | $176.37 | $216.25 | $0.00 | $46.86 |
| 2019 | $181.46 | $176.46 | $46.87 | $0.00 | $72.96 |
| 2020 | $171.14 | $160.65 | $0.77 | $0.00 | $4.50 |
| 2021 | $175.10 | $188.30 | $3.76 | $0.00 | $190.22 |
| 2022 | $183.88 | $175.06 | $0.00 | $0.00 | $42.39 |
| 2023 | $175.06 | $172.16 | $0.00 | $0.00 | $55.04 |
| 2024 | $168.51 | $176.34 | $13.57 | $0.00 | $71.48 |
| 2025 | $151.66 | $194.29 | $0.00 | $0.00 | $93.52 |
AI valuation
Our deep-learning model estimates Becton, Dickinson and Company's (BDX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $194.29
- Current price
- $149.31
- AI upside
- +30.13%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$60.66
-59.37% upside
Graham-Dodd
—
— upside
Graham Formula
$93.52
-37.36% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BDX | Becton, Dickinson and Com… | $149.31 | 63.94B | +30% | -59% | — | -37% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| IDXX | IDEXX Laboratories, Inc. | $656.73 | 52.44B | -34% | -40% | -88% | -64% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
- CEO
- Thomas E. Polen Jr.
- Employees
- 70K
- Beta
- 0.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($60.66 ÷ $149.31) − 1 = -59.37% (DCF, example).